# US 2006/0153860 A1 · Novel antigen-binding polypeptides and their uses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0153860 A1
- Document ID: US20060153860A1
- Status: Published application
- Kind: A1
- Application number: 11/155,909
- Filed: 2005-06-17
- Published: 2006-07-13
- Earliest claimed: 2004-06-18
- Assignees: Ambrx, Inc.
- Inventors: Ho Cho; Thomas Daniel; Troy Wilson; Thomas Cujec; Feng Tian; Anna-Maria Hays; Bruce Kimmel; Lillian Ho
- Web page: https://patentgrep.com/patent/US20060153860A1

## CPC

- C07K 16/2863: {against receptors for growth factors, growth regulators}
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- C07K 14/195: from bacteria
- C07K 14/47: from mammals
- C07K 16/32: against translation products of oncogenes
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/41: Glycosylation, sialylation, or fucosylation
- C07K 2317/55: Fab or Fab'
- C07K 2317/622: Single chain antibody (scFv)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Novel antigen-binding polypeptides (ABP) and uses thereof are provided.

## Claims

### Claim 1

An antigen-binding polypeptide comprising one or more non-naturally encoded amino acids.

### Claim 2 (depends on 1)

The antigen-binding polypeptide of claim 1, wherein the antigen-binding polypeptide comprises one or more post-translational modifications.

### Claim 3 (depends on 1)

The antigen-binding polypeptide of claim 1, wherein the antigen-binding polypeptide is linked to a linker, polymer, or biologically active molecule.

### Claim 4

An isolated nucleic acid comprising a polynucleotide that hybridizes under stringent conditions to an antigen-binding polypeptide-encoding polynucleotide, wherein the polynucleotide comprises at least one selector codon.

### Claim 5 (depends on 3)

A method of making the antigen-binding polypeptide of claim 3, the method comprising contacting an isolated antigen-binding polypeptide comprising a non-naturally encoded amino acid with a linker, polymer, or biologically active molecule comprising a moiety that reacts with the non-naturally encoded amino acid.

### Claim 6 (depends on 1)

A composition comprising the antigen-binding polypeptide of claim 1 and a pharmaceutically acceptable carrier.

### Claim 7 (depends on 6)

A method of treating a patient having a disorder modulated by ABP comprising administering to the patient a therapeutically-effective amount of the composition of claim 6.

### Claim 8 (depends on 4)

A cell comprising the nucleic acid of claim 4.

### Claim 9

A method of making an antigen-binding polypeptide comprising a non-naturally encoded amino acid, the method comprising, culturing cells comprising a polynucleotide or polynucleotides encoding an antigen-binding polypeptide comprising a selector codon, an orthogonal RNA synthetase and an orthogonal tRNA under conditions to permit expression of the antigen-binding polypeptide comprising a non-naturally encoded amino acid; and purifying the antigen-binding polypeptide.

### Claim 10

A method of modulating serum half-life or circulation time of an antigen-binding polypeptide, the method comprising substituting one or more non-naturally encoded amino acids for any one or more naturally occurring amino acids in the antigen-binding polypeptide.

### Claim 11

An antigen-binding polypeptide encoded by a polynucleotide wherein said polynucleotide comprises a selector codon, and wherein said polypeptide comprises at least one non-naturally encoded amino acid.

### Claim 12 (depends on 11)

A composition comprising the antigen-binding polypeptide of claim 11 and a pharmaceutically acceptable carrier.

### Claim 13

A bispecific ABP comprising a first ABP and a second ABP joined to each other wherein said first ABP and said second ABP bind specifically to different epitopes wherein said first ABP has binding specificity for at least one epitope on a first antigen, and the second ABP has binding specificity for a second epitope on the first antigen or a second antigen which is different from said first epitope, and wherein said bispecific ABP comprises at least one non-naturally encoded amino acid.

### Claim 14 (depends on 13)

A composition comprising a bispecific ABP of claim 13 and a pharmaceutically acceptable carrier.

### Claim 15 (depends on 14)

A method for treating a disease or condition, said method comprising administering to a patient in need thereof a therapeutically effective amount of the composition of claim 14.

### Claim 16 (depends on 13)

An ABP comprising the bispecific ABP of claim 13, coupled to a biologically active molecule.

### Claim 17 (depends on 13)

A method of detecting a cell or tissue expressing one or more antigens, said method comprising: contacting a cell or tissue with an ABP of claim 13 attached to a detectable label; and detecting said label wherein detection of said label in association with a cell or tissue indicates the presence of a cell or tissue expressing one or more antigens bound by the ABP.

### Claim 18

An antigen-binding polypeptide comprising a water soluble polymer linked by a covalent bond to the antigen-binding polypeptide at a single amino acid.

### Claim 19

An antigen-binding polypeptide comprising at least one linker, polymer, or biologically active molecule, wherein said linker, polymer, or biologically active molecule is attached to the polypeptide through a functional group of a non-naturally encoded amino acid ribosomally incorporated into the polypeptide.

### Claim 20

An antigen-binding polypeptide comprising a linker, polymer, or biologically active molecule that is attached to one or more non-naturally encoded amino acids wherein said non-naturally encoded amino acid is ribosomally incorporated into the polypeptide at pre-selected sites.

### Claim 21

A method of modulating immunogenicity of an antigen-binding polypeptide, the method comprising substituting one or more non-naturally encoded amino acids for any one or more naturally occurring amino acids in the antigen-binding polypeptide.

### Claim 22

An antigen-binding polypeptide wherein the polypeptide is selected from the group consisting of SEQ ID NO: 19, 21, 23, 24, 26, 28, 30, 31 or fragment thereof.

### Claim 23 (depends on 3)

The antigen-binding polypeptide of claim 3, wherein the antigen-binding polypeptide is linked to the linker, polymer, or biologically active molecule under denaturing conditions.
